Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001457-28

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the overall response rate (complete plus partial response) of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.


Critère d'inclusion

  • Advanced metastatic ovarian cancer